The following article was written by Rachel Gaffney. If you would like additional information, you can contact Rachel at rsg@ssd-help.org.

https://scopeblog.stanford.edu/2020/04/30/new-advances-toward-safely-targeting-immune-cells-to-pediatric-brain-tumors/

Since 2008, Cure ATRT Now, has been funding ATRT targeted research at Dana Farber & St Jude’s hospital. This inspiring story is the reaso...

We continue to fight to find a cure for ATRT. This is a long & complicated fight but we are making progress, albeit slowly. This is the r...

Epizyme announces first patient dosed in global clinical program. Dana Farber Cancer Institute and Cincinnati Children's Hospital are the...

New research posted to the We Can Help -> Research section of the web site. Pitfalls in Diagnosing AT/RT: Experiences From the European R...

This presentation contains a lot of information, much of it very technical. The study is not specific to AT/RT, but does include AT/RT pa...

Epizyme, Inc. a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced th...

For those just learning about AT/RT, here is an helpful post from the Dana Farber Cancer Institute: http://blog.dana-farber.org/insight/2...

Barcelona, Spain, November 20, 2014 – Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative person...